Pharmaceuticals company Sanofi Consumer Healthcare India announced Q2CY25 results The company reported a 28% YoY increase in Q2 revenue to Rs 2,209 million. Sales growth stood at 27.5% from Q1CY25 and 27.6% YoY from 2024. Profit after tax (PAT) for the quarter reached Rs 607 million, a 21% increase over Q1CY25. Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India, said: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.” Result PDF
Pharmaceuticals company Sanofi Consumer Healthcare India announced Q1CY25 results Q1CY25 Financial Highlights: The company reported revenue from operations of Rs 1726 million. PAT at Rs 500 million, which stands 12.9% above the last quarter of Q4CY24. An increase of Rs 2.4 per share, landing the EPS at Rs 21.7. Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India, said: “We continue to focus on strengthening our operations and continues to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.” Result PDF